RxDoctor Payments DataLook up a doctor →

Elias Akl, MD

Allergy & Immunology · Philadelphia, PANPI 1104176106

Payments from drug & device makers

$79,723in general payments, 2019–2025

Across 665 payments — averaging $119.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$67K
  • Pfizer$3K
  • GSK$2K
  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$674
  • plus $4K from 23 others

What the payments were for

  • Consulting fees$1,6702%
  • Speaking & faculty fees$58,63574%
  • Travel & lodging$4,9136%
  • Food & beverage$14,17518%
  • Education$3310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,723 in reported general payments places this provider in the 85th percentile of 175 allergy & immunology providers in Pennsylvania.

See all allergy & immunology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$27,574
Medicare patients
84
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko20$88,641
Dupixent PenDupilumab16$59,462
Ipratropium Bromide64$1,375
Fluticasone Propionate28$395
Albuterol Sulfate HfaAlbuterol Sulfate11$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire$66,903$88,64120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 allergy & immunology providers in Pennsylvania.

Other allergy & immunology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →